For many people living with COPD, every breath can become a struggle. The disease gradually damages the lungs, limiting airflow and making everyday activities increasingly difficult.
In the United Kingdom alone, dozens of people die from COPD every day, and the disease is one of the biggest reasons people are admitted to hospital. Although inhalers and other medicines help many patients, flare-ups remain common and can greatly reduce quality of life.
Now, doctors in London have begun offering a completely new type of treatment. Researchers from King’s College London helped develop and study dupilumab, an injectable medicine that works differently from traditional COPD therapies. Patients treated at Guy’s and St Thomas’ NHS Foundation Trust are the first in the country to receive the drug following its approval by NICE.
Most existing COPD treatments help relax the muscles around the airways or reduce inflammation in a broad way. Dupilumab instead targets two specific immune proteins called IL-4 and IL-13.
These proteins contribute to inflammation in a group of patients whose COPD is driven by eosinophils, a type of white blood cell. By blocking these signals, the medicine reduces airway swelling and mucus production.
Clinical studies found that patients receiving dupilumab experienced about 30% to 34% fewer COPD flare-ups each year than those receiving standard care alone. Preventing flare-ups is especially important because each episode can permanently damage lung function, increase the risk of hospitalization, and shorten life expectancy.
Another advantage is convenience. After receiving their first dose in hospital, many patients can learn to give themselves the injection every two weeks at home using an easy-to-use injection pen. Doctors will continue monitoring patients to ensure the treatment remains effective and safe over time.
The treatment is the result of decades of scientific research into eosinophilic inflammation. Professor Mona Bafadhel and her research team played a major role in showing that not all COPD patients have the same type of inflammation. This discovery has opened the door to more personalized treatment instead of relying on a one-size-fits-all approach.
Review and analysis: Dupilumab is an exciting addition to COPD care because it directly targets a biological pathway responsible for inflammation in selected patients. However, it is not a cure and will benefit only those with eosinophilic COPD.
Long-term monitoring will help determine whether the improvements seen in clinical trials continue over many years and whether the treatment reduces healthcare costs by preventing hospital admissions. Overall, the approval marks one of the most significant advances in COPD treatment in recent years.
If you care about lung health, please read studies about marijuana’s effects on lung health, and why some non-smokers get lung disease and some heavy smokers do not.
For more information about health, please see recent studies that olive oil may help you live longer, and vitamin D could help lower the risk of autoimmune diseases.
Source: King’s College London.
